A new drug called olpasiran can dramatically lower a harmful type of cholesterol called lipoprotein(a) in people with heart disease — at the highest dose, it doesn’t just reduce it, it nearly wipes it out completely compared to a dummy pill.
Evidence Quality Assessment
Claim Status
overstated
Study Design Support
Design supports claim
Appropriate Language Strength
probability
Can suggest probability/likelihood
Assessment Explanation
A 101.1% reduction in lipoprotein(a) implies levels dropped below zero, which is biologically impossible since concentrations cannot be negative. This suggests either a statistical artifact (e.g., mean reduction exceeding baseline due to variability or outlier effects) or misinterpretation of percent change calculation. The claim uses a definitive verb ('achieving') and presents an impossible outcome as fact. While dose-dependent reduction is plausible and supported by RNAi therapeutics, the magnitude is overstated. The claim should reflect uncertainty and clarify that the reduction is relative to baseline, not absolute.
More Accurate Statement
“In patients with established atherosclerotic cardiovascular disease, olpasiran reduces lipoprotein(a) in a dose-dependent manner, with the highest dose (225 mg every 12 weeks) associated with a placebo-adjusted mean reduction of approximately 101% at 36 weeks — a magnitude exceeding baseline levels, suggesting near-complete suppression in many individuals.”
Context Details
Domain
medicine
Population
human
Subject
Olpasiran
Action
reduces
Target
lipoprotein(a) in patients with established atherosclerotic cardiovascular disease
Intervention Details
Gold Standard Evidence Needed
According to GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this specific claim, ordered from strongest to weakest evidence.
Evidence from Studies
Supporting (1)
Small Interfering RNA to Reduce Lipoprotein(a) in Cardiovascular Disease.
Scientists tested a drug called olpasiran in heart disease patients with high levels of a harmful fat called lipoprotein(a). The higher the dose, the more the fat dropped — and the biggest dose cut it by over 100% compared to placebo. So yes, the drug works as claimed.